GlassScriptPhysician profile
Melissa B Behringer
NPI 1508861402
$9,654.41
in general payments reported to CMS, 2019-2025
42 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $1,290 · 2021: $1,876 · 2022: $1,630 · 2023: $1,644 · 2024: $1,640 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,358.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,128.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $889.66 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $864.63 | 2019-2024 | Repatha, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $647.72 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.30 | 2019-2024 | Jardiance |
| Pfizer INC. | $539.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $481.24 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $475.70 | 2019-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $433.34 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.85 | 2020-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $228.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $207.97 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $166.04 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $164.48 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $153.57 | 2019-2022 | |
| Abbvie INC. | $147.71 | 2021-2023 | Vraylar, Qulipta |
| Abbott Laboratories | $135.59 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $120.91 | 2019-2021 | |
| Corium, LLC | $88.75 | 2022-2024 | Azstarys |
| Phathom Pharmaceuticals, INC. | $87.34 | 2024 | Voquezna |
| Exact Sciences Corporation | $75.21 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $56.76 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $54.77 | 2021 | |
| Dexcom, INC. | $41.90 | 2021-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $32.40 | 2019-2020 | |
| Shire North American Group INC | $28.79 | 2019 | |
| Tandem Diabetes Care, INC. | $21.09 | 2022 | |
| Mylan Specialty L.P. | $18.90 | 2019 | |
| Hologic Sales and Service, LLC | $18.44 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.74 | 2021 | |
| Depuy Synthes Sales INC. | $16.28 | 2020 | |
| Medtronic, INC. | $16.03 | 2022 | |
| Adlon Therapeutics L.P. | $15.13 | 2020 | |
| Eisai INC. | $15.02 | 2020 | |
| Irhythm Technologies, INC. | $14.19 | 2023 | Zio Xt Patch |
| Averitas Pharma INC. | $14.17 | 2023 | Qutenza |
| Seqirus USA INC | $14.15 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Sanofi Pasteur INC. | $12.86 | 2020 | |
| Bioventus LLC | $12.85 | 2022 | |
| Medtronic Minimed, INC. | $12.50 | 2019 | |
| Genentech USA, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Behringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.